|
|
Article: Cytoclonal Pharmaceutics Announces New Business Strategy And Name Change to eXegenics.
- Article from:
- PR Newswire
- Article date:
- October 24, 2001
|
Copyright informationCOPYRIGHT 2001 PR Newswire Association, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- Company Adopts New 'Platform' Business Model -
NEW YORK, Oct. 24 /PRNewswire/ --
The new leadership team of Cytoclonal Pharmaceutics Inc. (Nasdaq: CYPH) today unveiled a new business strategy to move the Company towards a commercially viable, "platform" biotechnology company that can drive revenue-generating partnerships with its drug discovery technologies in the near term, and build an internal drug development pipeline to create longer-term value.
The company also announced a name change to eXegenics Inc. to reflect the new direction of the company. The name change will become official, and trading under the new Nasdaq symbol "EXEG" will ...
Related newspaper, magazine, and journal articles:
|
|
Article: Biopharmaceutical company enters research collaboration.
Health & Medicine Week;
November 17, 2003 ;
415 words
......identify small molecule lead compounds from a large portion of...successful biotechnology company like Neurocrine discover the lead compounds which will be their next...Biosciences is a biopharmaceutical company focused on the discovery...
|
|